Edition:
United Kingdom

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

258.50SEK
24 Sep 2018
Change (% chg)

1.10kr (+0.43%)
Prev Close
257.40kr
Open
257.40kr
Day's High
263.70kr
Day's Low
256.60kr
Volume
482,164
Avg. Vol
878,477
52-wk High
299.60kr
52-wk Low
107.40kr

Chart for

About

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers... (more)

Overall

Beta: 1.57
Market Cap(Mil.): kr34,172.46
Shares Outstanding(Mil.): 272.51
Dividend: --
Yield (%): --

Financials

  SOBIV.ST Industry Sector
P/E (TTM): 46.65 30.93 32.76
EPS (TTM): 2.69 -- --
ROI: 8.68 15.07 14.61
ROE: 12.91 16.59 16.33

CORRECTED-Sweden's Sobi buys rights for emapalumab drug, strengthening inflammation business

STOCKHOLM, July 20 Drugmaker Swedish Orphan Biovitrum (Sobi) said on Friday it had reached an exclusive licensing deal with Swiss firm Novimmune SA for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis.

20 Jul 2018

Earnings vs. Estimates